A team of scientists from the University of Michigan Medical School studied a line of stem cells derived from patients with bipolar disorder to determine what, if any, differences could be found between these and the cells of people without the disorder.
Read More
We’re all aware that neuroleptics and other dopamine-receptor blocking agents (DRBAs) can cause a variety of movement disorders, often referred to as extrapyramidal syndromes (EPS).
Read More
A major obstacle in the prevention of depression is the lack of a predictive biomarker in individuals who later develop the disorder. British researchers have shown that the combination of a physiological biomarker—salivary cortisol—and the presence of depressive symptoms might be used to predict the development of major depression in adolescents.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
